Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

Geisler, Jürgen, Haynes, Ben, Anker, Gun, Dowsett, Mitch, Lønning, Per Eystein·2002·Journal of Clinical Oncology
DOI 10.1200/jco.20.3.751

Cited by (606)

Items 301–400 of 606

  1. Anastrozole
    Keri Wellington, Diana M. Faulds · 2002 · Drugs
  2. Letrozole
    Gillian M. Keating · 2009 · Drugs
  3. Aromatase inhibitors: from bench to bedside and back
    Jürgen Geisler · 2007 · Breast Cancer
  4. In situaromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer
    Anne E. Lykkesfeldt, Katrine L. Henriksen, Birgitte Rasmussen, Hironobu Sasano, Dean B. Evans, Susanne Möller, Bent Ejlertsen, Henning T. Mouridsen · 2009 · BMC Cancer
  5. Stepwise estrogen suppression manipulating the estrostat
    Per Eystein Lønning · 2001 · The Journal of Steroid Biochemistry and Molecular Biology
  6. Neoadjuvant Endocrine Therapy in Primary Breast Cancer
    Jens Huober, U. Krainick‐Strobel, Raffael Kurek, Diethelm R. Wallwiener · 2004 · Clinical Breast Cancer
  7. Exemestane and aromatase inhibitors in the management of advanced breast cancer
    J. Michael Dixon · 2004 · Expert Opinion on Pharmacotherapy
  8. Aromatase Inhibitors for Treatment of Breast Cancer
    John R. Benson, O Ravisekar · 2007 · Current Cancer Therapy Reviews
  9. Landmark trials in endocrine adjuvant therapy for breast carcinoma
    William John Gradishar · 2006 · Cancer
  10. Life following aromatase inhibitors – where now for endocrine sequencing?
    Stephen R.D. Johnston, Lesley‐Ann Martin, Mitch Dowsett · 2005 · Breast Cancer Research and Treatment
  11. Breast Cancer Adjuvant Endocrine Therapy
    Tessa Cigler, Paul Edward Goss · 2007 · The Cancer Journal
  12. The evolving role of letrozole in the adjuvant setting: First results from the large, phase III, randomized trial BIG 1-98
    Alain Monnier · 2006 · The Breast
  13. Aromatase inhibitors: a safety comparison
    W. Jonat, Felix Hilpert, Manfred Kaufmann · 2007 · Expert Opinion on Drug Safety
  14. What Is the Optimal Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive Early Breast Cancer?
    Nadine Tung · 2013 · Journal of Clinical Oncology
  15. Fetal safety profile of aromatase inhibitors: Animal data
    Gian Mario Tiboni, Adalisa Ponzano · 2016 · Reproductive Toxicology
  16. Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin
    Nazli Bahrami, Shakila Jabeen, Andliena Tahiri, Torill Sauer, Hilde Presterud Ødegård, Stephanie Beate Geisler, Berit Gravdehaug, Laurens Cornelus Reitsma, Knut Selsås, Vessela N. Kristensen et al. · 2021 · Breast Cancer Research and Treatment
  17. Estradiol measurement in translational studies of breast cancer
    Per Eystein Lønning · 2014 · Steroids
  18. Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors
    Lidija Bošković, Maja Gašparić, Marija Petković, Damir Gugić, Ingrid Belac-Lovasić, Željko Soldić, Branka Petrić Miše, Nina Dabelić, Ljubica Vazdar, Eduard Vrdoljak · 2016 · The Breast
  19. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding?
    Per Eystein Lønning, Jürgen Geisler · 2009 · The Journal of Steroid Biochemistry and Molecular Biology
  20. Anastrozole vs Letrozole to Augment Height in Pubertal Males With Idiopathic Short Stature: A 3-Year Randomized Trial
    Walter Zegarra, Sayali A. Ranadive, Diane Toulan, E. Kirk Neely · 2024 · Journal of the Endocrine Society
  21. Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis
    Yehui Zhu, Theresa A. Koleck, Catherine M. Bender, Yvette P. Conley · 2019 · Biological Research For Nursing
  22. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane
    Nazli Bahrami, Gregory Chang, Noriko Kanaya, Torill Sauer, Daehoon Park, Marie Loeng, Berit Gravdehaug, Shiuan Chen, Jürgen Geisler · 2020 · The Journal of Steroid Biochemistry and Molecular Biology
  23. Hormonoradiothérapie adjuvante concomitante des cancers du sein : état de l'art
    D. Azria, C. Lemanski, A. Zouhair, Marian Gutowski, Yazid Belkacémi, Jean Bernard Dubois, Gilles Romieu, Mahmut Özşahin · 2004 · Cancer/Radiothérapie
  24. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: Where are we now?
    Michael Baum · 2005 · European Journal of Cancer
  25. Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration
    Taeko Nagao, Misako Kira, Masako Takahashi, Junko Honda, Toshiyuki Hirose, Akira Tangoku, Hitoshi Zembutsu, Yusuke Nakamura, Mitsunori Sasa · 2009 · World Journal of Surgical Oncology
  26. Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance
    Christopher C P Yiu, Hironobu Sasano, Katsuhiko Ono, Louis WC Chow · 2010 · Expert Opinion on Investigational Drugs
  27. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting
    Ajay S. Bhatnagar · 2006 · The Breast
  28. Cancer of the Breast
    Martin D. Abeloff, Antonio C. Wolff, Barbara L. Weber, Tal Z. Zaks, Vergilio Sacchini, Beryl L. McCormick · 2008 · Elsevier eBooks
  29. Clinical differences among the aromatase inhibitors.
    Jennifer A. Ligibel, Eric P. Winer · 2003 · PubMed
  30. Applicability of the Intratumor Aromatase Preclinical Model to Predict Clinical Trial Results With Endocrine Therapy
    Angela Brodie, Henning T. Mouridsen · 2003 · American Journal of Clinical Oncology
  31. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226
    Daniel L. Hertz, William Eric Barlow, KM Kidwell, Kathy S. Albain, Ted A. Vandenberg, Shaker R. Dakhil, Nagendra R. Tirumali, Robert B. Livingston, Julie R. Gralow, Daniel F. Hayes et al. · 2016 · British Journal of Clinical Pharmacology
  32. Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer
    K M Elliott, Jennifer E. Dent, Frank Z. Stanczyk, Laura Woodley, R. Charles Coombes, Agam Purohit, Carlo Palmieri · 2014 · British journal of surgery
  33. Effect of Letrozole on Plasma Lipids, Triglycerides, and Estradiol in Postmenopausal Women with Metastatic Breast Cancer
    Jamal Zidan, L. Chetver, Osamah Hussein, Miriam Zucker · 2010 · The Oncologist
  34. Compounds of Natural Origin and Acupuncture for the Treatment of Diseases Caused by Estrogen Deficiency
    Abhishek Thakur, Subhash Chandra Mandal, Sugato Banerjee · 2016 · Journal of Acupuncture and Meridian Studies
  35. Effects of Anastrozole on Lipid Metabolism Compared with Tamoxifen in Rats
    Yasuo Hozumi, Yoji Hakamata, Hideki Sasanuma, Shigeto Ogura, Hideo Nagai · 2002 · Breast Cancer Research and Treatment
  36. Reducing the risk of distant metastases in breast cancer patients: Role of aromatase inhibitors
    Lucia Del Mastro, Matteo Clavarezza, Marco Venturini · 2007 · Cancer Treatment Reviews
  37. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Henning T. Mouridsen, Nicholas J. Robert · 2005 · PubMed Central
  38. Aromatase inhibitors for prevention of breast cancer in postmenopausal women
    Lucy‐Ann Behan, Eitan Amir, Robert F. Casper · 2015 · Menopause The Journal of The North American Menopause Society
  39. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer
    Jason Robarge, Zereunesay Desta, Anne Nguyen, Lang Li, Daniel L. Hertz, James Michael Rae, Daniel F. Hayes, Anna Maria Storniolo, Vered Stearns, David Alastair Flockhart et al. · 2016 · Breast Cancer Research and Treatment
  40. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity
    Gurusamy Umamaheswaran, Kadambari Dharanipragada, Suresh Kumar Muthuvel, Sekar Kalaivani, Devi Jaganathan, Solai Elango Damodaran, Suresh Chandra Pradhan, Biswajit Dubashi, Steven Aibor Dkhar, Chandrasekaran Adithan · 2020 · Breast Cancer Research and Treatment
  41. Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review
    Melika Shirdarreh, Rossanna C. Pezo · 2021 · Breast Cancer
  42. Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor
    Peyman Hadji · 2010 · Breast Care
  43. Determination of Letrozole in Tablet Formulations by Reversed Phase High Performance Liquid Chromatography
    Mani Ganesh, K Rajasekar, Margandan Bhagiyalakshmi, Mari Vinoba, K Saktimanigandan, Hyun Tae Jang · 2010 · Tropical Journal of Pharmaceutical Research
  44. Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity
    Wei-Yun Guo, Shang-Ming-Zhu Zeng, Girdhar Singh Deora, Qingshan Li, Ban‐Feng Ruan · 2019 · Current Topics in Medicinal Chemistry
  45. Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial
    Mária Faltinová, Leena Vehmanen, Heli K. Lyytinen, Mikko Haanpää, Esa K Hämäläinen, Aila E. Tiitinen, CARL P. BLOMQVIST, Johanna Mattson · 2021 · Breast Cancer Research and Treatment
  46. Measurement of estrone sulfate in postmenopausal women: comparison of direct RIA and GC-MS/MS methods for monitoring response to endocrine therapy in women with breast cancer.
    Susannah Jane Stanway, Agam Purohit, Michael J. Reed · 2007 · PubMed
  47. Letrozole in the treatment of breast cancer
    Henning T. Mouridsen, Ajay S. Bhatnagar · 2005 · Expert Opinion on Pharmacotherapy
  48. Steroid Receptor Imaging in Breast Cancer
    Jean‐Mathieu Beauregard, Éric E. Turcotte, François Bénard · 2006 · PET Clinics
  49. Approach to the Peripubertal Patient With Short Stature
    Lournaris Torres‐Santiago, Nelly Mauras · 2024 · The Journal of Clinical Endocrinology & Metabolism
  50. Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004–2023)
    Xiao-Dong Chen, Kun-Hong Xiao, Chao-Bing Zhou · 2024 · Frontiers in Pharmacology
  51. Adjuvant Endocrine Therapy and Bone Health in Breast Cancer
    Gregory A. Clines, Palak U. Choksi, Catherine H. Van Poznak · 2015 · Current Osteoporosis Reports
  52. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole
    Valentina Sini, Gianluigi Lunardi, Massimo Cirillo, Monica Turazza, Claudia Bighin, Sara Giraudi, Alessia Levaggi, Patrizia Piccioli, Giancarlo Bisagni, Roberta Gnoni et al. · 2014 · British Journal of Cancer
  53. Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients
    Jürgen Geisler, Ian Smith, William R. Miller · 2011 · The Journal of Steroid Biochemistry and Molecular Biology
  54. Effects of SLCO1B1 Polymorphisms on Plasma Estrogen Concentrations in Women with Breast Cancer Receiving Aromatase Inhibitors Exemestane and Letrozole
    Jacqueline M Dempsey, KM Kidwell, Christina L. Gersch, Andrea M. Pesch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd C. Skaar, Daniel F. Hayes, Norah Lynn Henry et al. · 2019 · Pharmacogenomics
  55. Aromatase Inhibitors: An Overview for Surgeons
    Kai A. Bickenbach, Nora T. Jaskowiak · 2006 · Journal of the American College of Surgeons
  56. Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women?
    Paolo Carlini, Gianluigi Ferretti, Serena Di Cosimo, Elvira Colella, Riccardo Tonachella, Adriana Romiti, Federica Tomao, Antonio Frassoldati, Paola Papaldo, Alessandra Fabi et al. · 2003 · The Journal of Steroid Biochemistry and Molecular Biology
  57. Effects of decreased estradiol-17β on the serum and anterior pituitary IGF-I system in pigs
    C K Hilleson-Gayne, Jeffrey A. Clapper · 2005 · Journal of Endocrinology
  58. Treatments for Breast Cancer That Affect Cognitive Function in Postmenopausal Women
    Jeffrey D. Blaustein · 2017 · Policy Insights from the Behavioral and Brain Sciences
  59. Adjuvant Endocrine Therapy for Breast Cancer
    İbrahim Yıldız, Adnan Aydıner · 2018 · Springer eBooks
  60. Endocrine therapy and other targeted therapies for metastatic breast cancer
    Syed A. Hussain, Daniel H. Palmer, Sarah Moon, Daniel William Rea · 2004 · Expert Review of Anticancer Therapy
  61. Experience with Exemestane in the Treatment of Early and Advanced Breast Cancer
    Per Eystein Lønning, Jürgen Geisler · 2008 · Expert Opinion on Drug Metabolism & Toxicology
  62. Vaginal Gene Expression During Treatment With Aromatase Inhibitors
    Theodora Kunovac Kallak, Juliane Baumgart, Kerstin Nilsson, Helena Åkerud, Inger Sundström Poromaa, Anneli C. Stavreus-Evers · 2015 · Clinical Breast Cancer
  63. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer
    Murtuza M. Rampurwala, Kari Braun Wisinski, Mark E. Burkard, Sima Ehsani, Ruth M O'Regan, Lakeesha L. Carmichael, KyungMann Kim, Jill Kolesar, Amye Juliet Tevaarwerk · 2016 · Investigational New Drugs
  64. Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer
    Sudeep Gupta, Manish Kumar Singh, Amish D. Vora, Govind Babu, Muskan Walia, V. Nautial, R. Saha, B. Koppikar Smruti, Jitendra Sharma, R. Koul et al. · 2018 · South Asian Journal of Cancer
  65. Application of aromatase inhibitors in endocrine responsive breast cancers
    Paul Edward Goss, Melinda D. Wu · 2007 · The Breast
  66. The NEOLETEXE Trial: A Neoadjuvant Cross-Over Study Exploring the Lack of Cross Resistance Between Aromatase Inhibitors
    Nazli Bahrami, Torill Sauer, Siri Engebretsen, Belal Aljabri, Vahid Bemanian, Jonas Christoffer Lindstrøm, Torben Lüders, Vessela N. Kristensen, Annika Lorentzen, Marie Loeng et al. · 2019 · Future Oncology
  67. Development of Aromatase Inhibitors and Their Pharmacologic Profile
    Per Eystein Lønning, Jürgen Geisler, Ajay Bhatnager · 2003 · American Journal of Clinical Oncology
  68. The potential for aromatase inhibition in breast cancer prevention.
    Per Eystein Lønning, L E Kragh, Björn Erikstein, Anne Irene Hagen, Terje Risberg, Ellen Schlichting, Jürgen Geisler · 2001 · PubMed
  69. The FACE Trial: Letrozole or Anastrozole as Initial Adjuvant Therapy?
    W. Jonat, Christoph Mundhenke · 2007 · Cancer Investigation
  70. Sex-dependent effects of multiple acute concurrent stresses on memory: a role for hippocampal estrogens
    Rachael E. Hokenson, Yasmine H. Alam, Annabel K. Short, Sunhee Jung, Cholsoon Jang, Tallie Z. Baram · 2022 · Frontiers in Behavioral Neuroscience
  71. Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?
    Silvia Riondino, Vincenzo Formica, Elena Valenzi, Cristina Morelli, Valeria Flaminio, Ilaria Portarena, Francesco Torino, Mario Roselli · 2023 · Current Oncology
  72. Update on aromatase inhibitors in breast cancer
    Richard E. Gould, Agustin A. García · 2006 · Current Opinion in Obstetrics & Gynecology
  73. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients
    Daniel L. Hertz, Kelly A. Speth, KM Kidwell, Christina L. Gersch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd C. Skaar, Daniel F. Hayes, Norah Lynn Henry et al. · 2017 · Breast Cancer Research and Treatment
  74. Development, Characterization and In Vitro Evaluation of Paclitaxel and Anastrozole Co-Loaded Liposome
    Minh Thanh Vu, Dinh Tien Dung Nguyen, Ngoc Hoi Nguyen, Văn Thu Lê, The Nam Dao, Nguyen Thi Huong, Tien Dung Cong, Truc Le-Buu Pham, Tri Duc Lam, Ngoc Thuy Trang Le · 2020 · Processes
  75. The role of aromatase inactivators in the treatment of breast cancer
    Per Eystein Lønning · 2002 · International Journal of Clinical Oncology
  76. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: Why, who and how long?
    Manfred Kaufmann, Achim Rody · 2006 · European Journal of Obstetrics & Gynecology and Reproductive Biology
  77. Comparison between aromatase inhibitors and sequential use
    Per Eystein Lønning · 2003 · The Journal of Steroid Biochemistry and Molecular Biology
  78. Endocrine Effects of Nonsteroidal Aromatase Inhibitors and Their Clinical Impact
    Emilio Bajetta, Nicoletta Zilembo, Ettore Bichisao, Per Eystein Lønning, Jürgen Geisler, Mitch Dowsett · 2002 · Journal of Clinical Oncology
  79. Aromatase Inhibitors and Their Application to the Treatment of Breast Cancer
    Angela Brodie · 2002 · CRC Press eBooks
  80. Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement
    Mária Faltinová, Leena Vehmanen, Heli K. Lyytinen, Mikko Haanpää, Esa K Hämäläinen, Aila E. Tiitinen, CARL P. BLOMQVIST, Johanna Mattson · 2023 · Breast Cancer Research and Treatment
  81. Aromatase inhibitors in premenopause: Great expectations fulfilled?
    Rosalba Torrisi, Selene Rota, Agnese Losurdo, Monica Zuradelli, Giovanna Masci, Armando Santoro · 2016 · Critical Reviews in Oncology/Hematology
  82. Treatment of Short Stature with Aromatase Inhibitors: A Systematic Review and Meta-Analysis
    Jing Liu, Shujuan Yin, Yunyun Luo, Xi Bai, Shi Chen, Hongbo Yang, Huijuan Zhu, Hui Pan, Huijuan Ma · 2021 · Hormone and Metabolic Research
  83. Bone health in breast cancer
    Praful Pandey, Aparna Sharma, Ajay Gogia · 2023 · Current Problems in Cancer
  84. Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial
    Christos J. Markopoulos, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Basileios Venizelos, Vasilios Zobolas, John Misitzis, Grigorios Xepapadakis, Helen J Gogas · 2012 · Journal of Cancer Research and Clinical Oncology
  85. Effect of letrozole on urinary bladder function in the female rabbit
    Wei‐Yu Lin, Alexandra W. Rehfuss, Catherine Whitbeck, Yung‐Shun Juan, Paul Chichester, ANITA S. MANNIKAROTTU, Robert M. Levin · 2007 · British Journal of Urology
  86. Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison
    Georg Griesinger, Sören von Otte, A. Schultze-Mosgau, Klaus Diedrich, Andreas Schröer · 2008 · Fertility and Sterility
  87. Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk
    Ana María López, Sandhya Pruthi, Judy Caroline Boughey, Marjorie Perloff, Chiu-Hsieh Hsu, Julie E. Lang, Michele Ley, Denise H. Frank, Josephine Amalia Taverna, H.‐H. Sherry Chow · 2015 · Cancer Prevention Research
  88. Treatment with aromatase inhibitors and markers of cardiovascular disease
    Eva Blondeaux, Debora Musio, Paolo Bruzzi, Matteo Lambertini, Valerio Gazzola, Francesca Benedetta Poggio, Stefania Vecchio, Alessia Levaggi, Alessia D’Alonzo, Maria Cecilia Perfumo et al. · 2016 · Breast Cancer Research and Treatment
  89. Bone health and osteoporosis screening in gynecologic cancer survivors
    Janelle N. Sobecki, Laurel W. Rice, Ellen M. Hartenbach · 2020 · Gynecologic Oncology
  90. Background and development of aromatase inhibitors
    William R. Miller · 2008 · Birkhäuser Basel eBooks
  91. Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer
    Ander Urruticoechea, Helena Aguilar, Xavier Solé, Gabriel Capellá, Lesley‐Ann Martin, Mitch Dowsett, Josep Ramón Germà-Lluch · 2007 · Breast Cancer Research and Treatment
  92. Letrozole in the treatment of breast cancer
    Matthew J Ellis, Heather S Shaw · 2002 · Expert Opinion on Pharmacotherapy
  93. Letrozole for the management of breast cancer
    Paul Edward Goss, Robert E Smith · 2002 · Expert Review of Anticancer Therapy
  94. Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
    Bjørn-Erik Bertelsen, Kristin Viste, Thomas Helland, Magnus Hagland, Håvard Søiland, Jürgen Geisler, Tone Hoel Lende, Per Eystein Lønning, Jørn Vegard Sagen, Gunnar Mellgren et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
  95. Is There a Survival Difference Between Male and Female Breast Cancer Subtypes According to the Prognostic Staging System? A Population-Based Cohort Study
    Ahmet Necati Şanlı, Deniz Esin Tekcan Şanlı, Mustafa Kadri Altundag, Fatih Aydoğan · 2023 · The American Surgeon
  96. Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin
    Lev M. Berstein, A. Koskela, Marina P. Boyarkina, Herman Adlercreutz · 2010 · Neoplasma
  97. Challenges in Clinical Patient Management
    Matti Aapro · 2010 · Cancer Investigation
  98. Escherichia coli biotransformation of daidzein fermentation products from soy‐based foods—relevance to food oestrogenicity‐based functionality
    Hui Ye, Samantha Z. Dudley, Ian C. Shaw · 2017 · International Journal of Food Science & Technology
  99. Joint symptoms associated with anastrozole and letrozole in patients with breast cancer: a retrospective comparative study
    Yoshihito Morimoto, Shuhei Sarumaru, Yuko Oshima, Chiho Tsuruta, Kazuhiro Watanabe · 2017 · Journal of Pharmaceutical Health Care and Sciences
  100. Letrozole targets the human ether‐a‐go‐go–related gene potassium current in glioblastoma
    Tyler Shugg, Nimita Dave, Enoch Amarh, Abdullah A Assiri, Karen E. Pollok, Brian R. Overholser · 2020 · Basic & Clinical Pharmacology & Toxicology